The infusion of $115 million accelerates development of a potentially disease‑modifying Parkinson’s treatment, positioning Aspen as a frontrunner in personalized regenerative therapy and attracting further biotech investment in the neuro‑degeneration space.
Comments
Want to join the conversation?
Loading comments...